| Outcome Measures: |
Primary: The incidence of overt nephropathy, overt nephropathy is defined as any one of the events described below: （1） UACR greater than 300 mg/g Cr; (2) 24 h urinary albumin greater than 300 mg; (3)doubling of the serum creatinine level to at least 200 μmol per liter; (4)the need for renal-replacement therapy;(5) death due to renal disease., 3 years | Secondary: The proportion of patients achieving at least a 15% reduction in UACR, Renal outcome, 3 years|Changes in estimated Glomerular Filtration Rate (eGFR), Renal outcome, 3 years|The number of patients who have new or worsening diabetic neuropathy, diabetic neuropathy was assessed based on biothesiometer., 3 years|The number of patients who have new or worsening diabetic retinopathy, Diabetic retinopathy was diagnosed according to the six-level grading scale of the European Community- funded Concerted Action Programme into the Epidemiology and Prevention of Diabetes (EURODIAB), 3 years|changes in CIMT from baseline to the 3rd year, cardiovascular outcome, 18 months and 3 year|The number of patients who have new cardiovascular events, cardiovascular events include death from cardiovascular causes, nonfatal stroke, nonfatal myocardial infarction, coronary-artery bypass grafting, percutaneous coronary intervention or revascularization for peripheral atherosclerotic arterial disease, and amputation because of ischemia, 6 years|changes of UACR, evaluated at 6, 12, 18, 24, 36, 48, 60, 72 months, 6 years|changes of eGFR, evaluated at 6, 12, 18, 24, 36, 48, 60, 72 months, 6 years|Death from any cause, All-cause mortality, 6 years
|
